ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences ® (Caris) announced today a multi-year research collaboration wherein Caris is pairing its highly sophisticated and comprehensive ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announces the following cancer researchers as the recipients of the organization’s annual scientific leadership and mentorship awards. Through its ...

Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study This phase II trial of ...